Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial

  title={Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial},
  author={François Boureau and Pascale Legallicier and Marmar Kabir-Ahmadi},
Tramadol in the Treatment of Neuropathic Cancer Pain
Tamadol is a therapeutic option for the control of neuropathic pain in patients with cancer, and appears to improve quality of life in these patients, and the analgesic effect is independent of changes in anxiety, depression and nervous system function.
Tramadol in Neuropathic Pain After Spinal Cord Injury: A Randomized, Double-blind, Placebo-controlled Trial
Tramadol might be tried for neuropathic pain after SCI after the use of gabapentin/pregabalin, and tricyclic antidepressants have been found to be insufficient.
Therapeutic Options for the Treatment of Postherpetic Neuralgia: A Systematic Review
Evidence for Food and Drug Administration-approved and off-label therapies for the treatment of Postherpetic neuralgia and to present gaps in the current literature for future research focus are summarized.
Real-World Treatment of Post-herpetic Neuralgia with Gabapentin or Pregabalin
It appears that gabapentin and pregabalin are not used effectively to treat PHN, and suboptimal dosing and discontinuation may be associated with supplementary use of other analgesics, especially opioids.
Efficacy of Pain Relief in Different Postherpetic Neuralgia Therapies: A Network Meta-Analysis.
Analgesics were preferable to other treatments with respect to pain relief for PHN, while antivirals appeared to be less effective than other therapies, although there is a lack of direct head-to-head comparisons of some treatments.
Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic Review
The evidence base supports the oral use of tricyclic antidepressants, certain opioids, and gabapentinoids in PHN, and a single study of spinal intrathecal administration of lidocaine and methylprednisolone demonstrated efficacy, although this has yet to be replicated.
An update on the treatment of postherpetic neuralgia.
Randomized controlled trial of the combined monoaminergic and opioid investigational compound GRT9906 in painful polyneuropathy
In this randomized, double‐blind, placebo‐controlled, three‐way cross‐over trial in painful polyneuropathy, GRT9906 demonstrated analgesic efficacy with a magnitude of effect comparable with tramadol and was well tolerated.
Acupuncture for the treatment of severe acute pain in Herpes Zoster: results of a nested, open-label, randomized trial in the VZV Pain Study
This controlled and randomized trial provides the first evidence of a potential role of AC for the treatment of acute herpetic pain in patients with Herpes Zoster.


Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia.
Controlled-release oxycodone is an effective analgesic for the management of steady pain, paroxysmal spontaneous pain, and allodynia, which frequently characterize postherpetic neuralgia.
Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy
The results of this placebo-controlled trial showed that tramadol was effective and safe in treating the pain of diabetic neuropathy and no statistically significant treatment effects on sleep were identified.
Antidepressants and anticonvulsants for diabetic neuropathy and postherpetic neuralgia: a quantitative systematic review.
Post-Herpetic Neuralgia in Older Patients
The most effective treatment of established PHN to date consists of adrenergic-ally active antidepressants, and there is a strict correlation with the brevity of the interval between acute shingles and initiation of such treatment.
Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia
The results show that neuropathic pain can respond to opioids and to systemically administered local anesthetic drugs.
Risk factors for postherpetic neuralgia.
Increased age and prodromal symptoms are associated with higher prevalence of PHN 1 and 2 months after onset of zoster and systemic acyclovir appears not to confer any protection against PHN, although benefit among elderly patients cannot be excluded.
Assessment of pain in herpes zoster: lessons learned from antiviral trials.